Status:
COMPLETED
Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Conditions:
Diabetes After Total Pancreatectomy
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Glucagon is a 29-amino acid peptide hormone of essential importance for glucose homeostasis. Hitherto glucagon has been believed to be secreted only from the pancreas, but recent studies show that glu...
Eligibility Criteria
Inclusion
- Pancreatectomised patients
- Caucasian above 30 years of age who have undergone total pancreatectomy
- Blood haemoglobin \>7.0 mmol/l for males and \>6.5 mmol/l for females
- Informed consent
- Non-diabetic control subjects
- Normal fasting plasma glucose and normal HbA1c (according to the World Health Organization (WHO) criteria)
- Normal blood haemoglobin
- Caucasian above 30 years of age
- Informed consent
Exclusion
- Pancreatectomised patients
- Pancreatectomy within the last 3 months
- Ongoing chemotherapy or chemotherapy within the last 3 months
- Treatment with GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors within the last 3 months
- eGFR\<60 ml/min/1,73m2 and/or albuminuria
- Known liver disease (excluding simple steatosis) and/or serum alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) \>3 × upper normal limit)
- Pregnancy and/or breastfeeding
- Age above 85 years
- Uncontrolled hypertension and/or significant cardiovascular disease
- Any condition that the investigator feels would interfere with trial participation
- Non-diabetic control subjects
- Diabetes or prediabetes (according to WHO criteria)
- First-degree relatives with diabetes
- eGFR\<60 ml/min/1,73m2 and/or albuminuria
- Known liver disease (excluding simple steatosis) and/or serum ALAT and/or serum ASAT \>3 × upper normal limits)
- Pregnancy and/or breastfeeding
- Age above 85 years
- Uncontrolled hypertension and/or significant cardiovascular disease
- Any condition that the investigator feels would interfere with trial participation
Key Trial Info
Start Date :
April 2 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 20 2019
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04061473
Start Date
April 2 2019
End Date
August 20 2019
Last Update
September 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Clinical Metabolic Research
Hellerup, Capital Region, Denmark, 2900